



UPDATE: Update to communications issued on 27th August 2024. Material updates are shown in **bold**.

Medicine Supply Notification

MSN/2024/092U

Isosorbide mononitrate 60mg modified-release tablets and capsules

Tier 2 – medium impact*

Date of issue: 17/09/2024

Link: [Medicines Supply Tool](#)

Summary

- Chemydur[®] 60XL tablets are out of stock until **late September 2024**.
- Monomax[®] XL 60mg tablets are out of stock until early October 2024.
- Monomil[®] XL 60mg tablets are in limited supply until late December 2024.
- Nyzamac[®] SR 60mg capsules are out of stock until late October 2024.
- Isotard[®] 60XL, Medomon[®] XL, Relosorb[®] XL and Tardisc[®] XL 60mg tablets remain available and can support the increased demand.
- Other brands of isosorbide mononitrate 60mg modified-release tablets are available, however cannot support the increase in demand.
- **Serious Shortage Protocols (SSP) for Chemydur[®] 60XL, Monomax[®] XL and Monomil[®] XL 60mg tablets, and Nyzamac[®] SR 60mg capsules were issued on 06/09/2024.**

Actions Required

No new patients should be initiated on Chemydur[®] 60XL, Monomax[®] XL, Monomil[®] XL 60mg modified-release tablets or Nyzamac[®] SR 60mg capsules until the supply issues have resolved.

Where existing patients have insufficient supply to last until the re-supply date(s), prescribers should:

- consider prescribing isosorbide mononitrate 60mg modified-release tablets generically, to enable any available brand to be dispensed, where appropriate; or
- consider prescribing an available alternative brand of isosorbide mononitrate 60mg modified-release tablet, and
- take into account patient history and previous hypersensitivity, or adverse reactions if prescribing an alternative brand.

Pharmacists and dispensing doctors:

Where a prescription for Chemydur[®] 60XL, Monomax[®] XL or Monomil[®] XL 60mg tablets, or Nyzamac[®] SR 60mg capsules is presented and cannot be fulfilled:

- **supply an alternative isosorbide mononitrate 60mg modified-release tablet according to the products specified in [SSP073 - SSP076](#);**

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

- ensure the cautions and exclusion criteria are taken into account when considering using an SSP;
- ensure patients/ carers are counselled regarding the substitute product;
- if the patient is deemed ineligible or does not consent to receive an alternative product via the SSP, they should be promptly referred back to the prescriber.

Patient reassurance may be needed when switching between brands of isosorbide mononitrate modified release preparations. Prescribers and pharmacy teams should counsel patients on the change and possible adverse events they may experience, particularly in the first few days, the most important being hypotension, tachycardia, and worsening headaches. If they have concerns, patients should be advised to contact their doctor.

Supporting information

Chemydur[®] 60XL, Monomax[®] XL, Monomil[®] XL 60mg MR tablets and Nyzamac[®] SR 60mg MR capsules are licensed for the prophylactic treatment of angina pectoris. They are administered once daily in the morning, up to a maximum dose of 120mg once daily. In new patients, the dose can be titrated to minimise the possibility of headache, by initiating the treatment with 30mg (half tablet), or with a lower dose capsule, for the first 2 – 4 days. For patients transitioning between brands, dose titration may also be required if they experience loss of efficacy or side effects after switching.

Links to further information

[SmPC Monomil[®] XL 60mg Tablets](#)
[SmPC Chemydur[®] 60XL Tablets](#)
[SmPC Monomax[®] XL 60 mg Tablets](#)
[SmPC Nyzamac[®] SR Capsules](#)
[SmPC Isotard[®] 60XL Tablets](#)

[SmPC Relosorb[®] XL Tablets](#)
[SmPC Medomon[®] XL 60mg Tablets](#)
[SmPC Tardisc[®] XL 60 Tablets](#)
[BNF: Isosorbide mononitrate](#)
[**NHSBSA Serious Shortage Protocols**](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.